BCF, Instrumentation Concept and VetSonic have collected 'VetSurgeon.org Best Stand Awards'; the first two at BEVA Congress and the latter at BCVA Congress.
Judging for the BEVA Congress awards was undertaken by members of BEVA Council. BCF picked up the Best Large Stand Award which was presented by outgoing President, Andrew Harrison.
Pictured left to right: BEVA President, Andrew Harrison, Gavin Mitchell and Carole Irvine of BCF, and John Alborough representing VetSurgeon.org.
Instrumentation Concept picked up the Best Shell Scheme Award
Pictured left to right: Outgoing BEVA President, Andrew Harrison; Tahir Afzac of Instrumentation Concept; John Alborough representing VetSurgeon.org, and Sheraz Ishaque of Instrumentation Concepts
At BCVA Congress, Vetsonic won the Best Stand Award.
Pictured left to right: Clare Walsh, Vetsonic Director; John Alborough, All Round Good Egg representing VetSurgeon.org; Gareth Hateley, then President BCVA and Sarah Vermont, Marketing Manager Vetsonic.
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
Mr Chalkley faced three charges against him. The first was that he failed to identify some or all of the animals tested with Intradermal Comparative Tuberculin (ICT) tests at the farm.
The second charge was that Mr Chalkley had certified that he had carried out ICT tests on 279 animals at the farm and recorded the results on the accompanying paperwork but had, in fact, not adequately identified some or all of the 279 animals and had fabricated the skin thickness measurements recorded for some of them.
In addition, the charge alleged that Mr Chalkley’s conduct was dishonest, misleading and risked undermining government testing procedures designed to promote public health.
The third charge was that between June 2011 and September 2018, Mr Chalkley received payment of approximately £20,000 for ICT tests when, as a result of his conduct in relation to ICT tests at the farm, he was not entitled to such payment.
At the outset of the hearing Mr Chalkley admitted the first charge, that he had not adequately identified some of the animals.
On the third day of the hearing, during his evidence to the Committee, he admitted that his certification of the ICT testing was therefore misleading.
He denied the rest of the charges including that his conduct had been dishonest and that it had risked undermining government testing procedures designed to promote public health.
In considering the charges against Mr Chalkley, the Committee heard that discrepancies regarding the tests that were carried out on the farm in March 2018 were originally raised by the Animal and Plant Health Agency (APHA), on whose behalf Mr Chalkley carried out ICT testing in his capacity as an Official Veterinarian.
When Mr Chalkley gave evidence during the hearing, he explained that he had taken over TB testing for the farm in 2008 and that working conditions on the farm had been difficult throughout the whole period 2008 to 2018. He stated that due to the harsh weather conditions of early 2018, TB testing was difficult, and that the farmer needed to complete the test by March 2018 to avoid a financial penalty.
Mr Chalkley explained that one of the reasons for there being limited time available for him to carry out the test within the time required by the farmer was that he was due to provide veterinary cover at the Cheltenham races the following week and he was unable to find anyone else to cover the tests. Mr Chalkley also explained that during the tests on 5 and 8 March there had been limited farmhands available to assist in processing the cattle through the tests.
In the course of being asked questions by counsel for the RCVS, Mr Chalkley accepted that he had failed to identify some 45% of the animals he had injected on 5 March 2018 and had, in respect of each of the skin thickness measurements for those animals, randomly chosen a figure that he believed would be appropriate based on the breed, age and sex of the animal.
The APHA guidelines state that specific measurements should be made and recorded for each individual animal using callipers. Mr Chalkley said that he could not remember seeing the “pop-up” declaration which appeared when submitting the results to the APHA online and had never read it. He stated that he was not aware that he was making a declaration. However, he accepted that as an Official Veterinarian he was confirming that he had carried out the test properly. While he agreed that he knew that the test contained inaccuracies, he did not accept that he was being dishonest when he submitted the results.
Having considered all the evidence put forward by the RCVS and Mr Chalkley in his own defence, the Committee found that Mr Chalkley had acted dishonestly in deliberately choosing not to take the measurements on 5 March and had instead submitted fabricated alternatives, and so risked undermining public health by failing to carry out his duties as an OV.
The Committee also concluded that Mr Chalkley had been acting dishonestly, as he knew that he was submitting the test results as if they were the authentic outcome of a properly conducted test when in reality, they were no such thing.
The Committee did not accept Mr Chalkley’s evidence that he was unaware of the declaration which accompanied the submission of the test outcome. The Committee therefore found both the first and second charges proved.
In respect of the third charge the Committee found that this was not proven noting that the RCVS had not disproved Mr Chalkley’s explanation regarding his reasons for returning the £20,000 in fees he had received for carrying out TB testing at the farm from the APHA since 2011.
The Committee then considered whether the first two charges, both of which had been found proven, amounted to serious professional misconduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee was prepared to accept that the respondent considered the risk arising from his actions as negligible. Nonetheless, in the Committee’s assessment a real risk existed due to the respondent’s actions and it was precisely the risk which the authorised testing procedure was designed to negate. The simple fact is the respondent could not be sure that each animal he assessed on 8 March 2018 had also been seen by him on 5 March 2018.
“However, the wider point with which the Committee was concerned related to the importance of any member of the profession or public being able to rely absolutely on the integrity of veterinary certification. Those parts of the Code and supporting guidance [concerning certification]… were unequivocal. It was very difficult to conceive of circumstances in which it could ever be justifiable to certify the outcome of a test which had not, in fact, been conducted in a way which was demonstrably valid and reliable. Such conduct was bound to be regarded as disgraceful by members of the profession and the general public.
“Honesty is the bedrock of appropriate certification and the Code and Guidance for the Disciplinary Committee is also unequivocal. Dishonesty in professional practice is always an extremely serious matter and the respondent’s responsibilities in the discharge of his functions as an Official Veterinarian were clear. On this occasion those responsibilities had been compromised.
“For these reasons, the Committee has come to the conclusion that the respondent’s conduct in relation to the facts found proved was disgraceful conduct in a professional respect.”
The Committee then went on to consider the sanction for Mr Chalkley.
The Committee heard oral evidence in mitigation, including from a former colleague who had worked with him in practice since 2006, as well as receiving a large number of written testimonials from various sources that attested to his honesty, integrity, willingness to help others, and charitable work in support of animal welfare.
Mr Chalkley’s counsel, in mitigation, highlighted his long and previously unblemished career, and characterised the conduct as an inexcusable but explicable error of judgement that was entirely isolated and out-of-character. Mr Chalkley’s counsel added that he had not done anything that he thought was seriously wrong, and there was no evidence that any harm had been done and that any risk to public health was not serious.
The Committee accepted that the conduct was isolated and out-of-character and that, furthermore, Mr Chalkley had made early and frank admissions to the APHA and that he had displayed a degree of insight, although the Committee was less confident that he truly understood the seriousness of the potential consequences of his dishonest conduct.
The Committee took into account the aggravating factors, including Mr Chalkley’s breach of trust of his position as an OV, the undermining of the integrity of veterinary certification, dishonesty and the potential public health impacts of his conduct.
Ian Arundale added: “The Committee considered that, having regard to the mitigating features which it had identified, a suspension order would be sufficient to send to the profession and the public a clear signal about the importance to be attached to accurate certification. The Committee considered that in the particular circumstances of this case, a period of three months suspension would be sufficient to achieve this objective.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
MSD has announced that the broad-spectrum clostridial disease vaccine for sheep and cattle, Bravoxin 10, is now available in a new 6 x 100ml farm vaccination pack. The pack contains enough vaccine for 600 sheep or 300 cattle boosters.
Buyers of the new farm pack will also get a free vaccine applicator worth £20. The new Bravoxin 10 applicator benefits from the sterimatic system, which protects and sterilises the vaccination needle with each injection. MSD says it can also be placed down between doses without risk of needle damage, self-injection or needing to remove the vaccine bottle.
Bravoxin 10 protects both cattle and sheep from clostridial diseases like blackleg and black disease, as well as other conditions caused by clostridial bacteria that usually kill the animal once infection has become established. The vaccine protects against disease caused by the 10 main clostridial bacteria; C. perfringens type A, C.perfringens type B, C.perfringens type C, C.perfringens type D, C.novyi type B, C.septicum, C.tetani, C.sordellii, C.haemolyticum and C.chauvoei.
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.
Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.
Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.
Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.
Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.
Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.
Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"
Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals. We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "
Fluboral controls gastro-intestinal nematodes including Ascaridia galli (adult stages), Heterakis gallinarum (adult stages) and Capillaria spp. (adult stages) in chickens and Ascaris suum (adult and L4 intestinal stages) in pigs.
Dechra says Fluboral’s formula allows it to mix in drinking water quickly and easily with five seconds of stirring.
Fluboral has a guaranteed 24-hour stability without sedimentation of the suspension after dilution in drinking water and Dechra says there is no risk of inhomogeneous mixing.
Johnny Wells West, key account manager – pig and poultry at Dechra, said: “Fluboral is a welcome addition to our Solustab range of water-soluble products, providing effortless and efficient parasite control in drinking water to enable farmers and producers to start medication quickly and cost-effectively, as and when needed.”
https://www.dechra.co.uk/products/livestock/prescription/fluboral#Fluboral.
Cryptisel is for use in reducing oocyst shedding in calves where diarrhoea caused by Cryptosporidium is a problem. After the presence of the causal organism has been established, Forte says Cryptisel can be used in all new-born calves to break the cycle of transmission and multiplication on-farm.
Dr John Henderson, Large Animal Product Manager with Forte Healthcare Ltd said: "Cryptisel will be a very useful medicine in the control of the most commonly-identified scour pathogen in the UK and Ireland. Used alongside the calf-rearing cornerstones of good colostrum management, hygiene, and biosecurity, Cryptisel will reduce production of Cryptosporidium oocysts and help limit spread of the disease among susceptible calves."
Cryptisel is a POM, available in 490ml and 980ml bottles. Both sizes come with a metered dosing pump for convenient administration.
For further information, contact your local Forte Territory Manager or email enquiries@fortehealthcare.com.
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
References
Virbac has launched Neoprinil, an eprinomectin pour-on solution indicated for use against internal and external parasites in cattle, including gut and lungworms, mange mites, sucking and chewing lice, horn flies and warbles.
Neoprinil has a zero-day withdrawal period in milk and can be administered using the company's Farmpack and Flexibag.
The Farmpack is a backpack which holds a Flexibag of Neoprinil solution. The Flexibag is a bag designed to protect medication and preserve it once it has been opened. The two together were awarded the 2014 PharmaPack Award for Innovative Packaging.
Neoprinil offers a one year stability period once it has first been opened and requires no special conditions for storage. It is presented in 2.5L, 4.5l and 8l pack sizes.
Product Manager for Large Animals Brigitte Goasduf MRCVS said: "A high worm burden can have adverse effects on the herd's productivity and performance and so it is advisable to ensure infected animals are treated as part of a Herd Health Plan. Eprinomectin is a tried and trusted parasiticide and studies confirm that it can have a positive impact on both milk production and on weight gain. Its zero day withdrawal period is a major benefit for dairy farmers.
"With the launch first of Deltanil and, now, Neoprinil, we are reinforcing our commitment to work with veterinary surgeons and farmers to understand the everyday challenges they face and to provide practical, effective solutions. We offer a comprehensive parasiticide range with a dispensing system that sets a new standard for convenience and ease of use."
Merial Animal Health has been found in breach of the NOAH Code of Practice for literature promoting the wormer Ivomec Super.
In the literature, Merial stated that Closantel injection (Janssen Animal Health) was effective against flukes aged 9 weeks or older, when in fact, at the time the undated brochure was distributed, Closantel was effective against flukes aged 7 weeks or older.
Merial did not dispute the facts alleged: the company had relied on an out-of-date detailer. The NOAH Code of Practice Committee emphasised the need for members to ensure, when giving comparative data in promotions, that up-to-date data is used. The SPC of any authorised product can be viewed on the VMD's website.
The Committee did commend Merial Animal Health for taking corrective action within two days of notification by the Complainant.
NOAH encourages those interested in finding out more to read the full details of the Committee's rulings on the NOAH website at www.noah.co.uk/code.
Each SoundTalks device has a microphone which covers up to a 10-metre radius.
Noises are transmitted to the cloud where sounds are analysed using algorithms which Boehringer says use many years of data, and with the use of AI are constantly evolving.
The company says the device, which monitors coughing 24/7, has already been shown to detect respiratory disease in pigs up to five days sooner than conventional methods, allowing vets and farmers to respond quicker, improving health outcomes, and minimising the risk of infection across the herd. 1,2
Paul Thompson BA VetMB MRCVS from Garth Pig Practice said: “The earlier we can detect the onset of disease the quicker we can intervene.
"By taking action earlier we can aim to reduce morbidity and mortality, and potentially lessen treatments including antibiotic use.
"This will help improve the wellbeing of the pigs and reduce the time commitments and costs for the farmer.
"Having heard how SoundTalks is already transforming the practices of producers and vets in other parts of Europe, I am excited to use it in my own day-to-day role.
"This innovation has the potential to provide robust data as to when respiratory disease starts, allowing us to refine our prevention plans and improve the overall health of the pigs.”
www.soundtalks.com
Henry, who works at Crowshall Veterinary Services in Norfolk, graduated from the Royal Veterinary College in 2018.
He is the lead products export vet for Crowshall and was instrumental in the business’s preparation for Brexit.
He is also one of the founding ‘green champions’ at the practice, which has become the first specialist poultry practice to be accredited with Investors in the Environment.
The panel of seven judges from said that within just three years Henry has gained much experience, showing evidence that he has contributed to reduced antibiotic usage as well as improved biosecurity and improved bird welfare, health and production for his clients.
They said: “He has clearly shown he has worked with colleagues as a team, and has introduced new initiatives in his practice including improving mental health of staff and assisting in sustainability.”
James Porritt, National Pig and Poultry Sales Manager of award sponsors Zoetis, said all three finalists were very strong candidates: “It was great to see the work they have all done recognised at the awards.
"It was fantastic to see Henry win and hope the award spurs him on to continue his bright future in the poultry industry.”
Photo: Henry Lamb holding the Young Farm Vet trophy, alongside Jonathan Agnew (left) and James Porritt of the award sponsors Zoetis
The Veterinary Record has published what the British Homeopathy Association is calling the first ever systematic review of randomised controlled trials (RCTs) in veterinary homeopathy.
The review was conducted by Dr Robert Mathie, research development adviser to the association, and Dr Jürgen Clausen from the Carstens Foundation, Germany.
They found 18 placebo-controlled RCTs of veterinary homeopathy, published in the peer-reviewed literature, that were eligible for detailed assessment. Of these, only two were judged to provide reliable evidence. The remainder were unclear or had a high risk of bias.
The two studies which were judged reliable were:
HEKTOEN, L., LARSEN, S., ØDEGAARD, S. A. & LOKEN, T. (2004) Comparison of homeopathy, placebo and antibiotic treatment of clinical mastitis in dairy cows - methodological issues and results from a randomized-clinical trial. Journal of Veterinary Medicine. A, Physiology, pathology, clinical medicine 51, 439-446. In this study, homeopathy was shown to be ineffective.
Dr Mathie said: "Up to now, debates about the efficacy or effectiveness of veterinary homeopathy have been polarised by the absence of any systematic review of the subject. Our work clarifies the nature of the current RCT evidence."
Mr Mark Elliott, immediate past president of the British Association of Homeopathic Veterinary Surgeons, said: "This important study affirms that reliable evidence does exist and that more research should be done, particularly in light of current concerns about antibiotic resistance in production animals."
It seems a remarkable admission, that the entire veterinary homeopathy edifice rests upon one study in piglets. However, if that study did prove the efficacy of homeopathy, it would of course be an order of magnitude more remarkable than today's admission.
So, no pressure then, Camerlink et al!
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
Current estimates suggest that around 95,000 calves, 30 million chicks and 3,000 Billy kids are affected per year.
The new position calls for solutions based on the overarching principle that quality of life should take precedence over lifespan, with the longer-term aim to move away from the production of unwanted animals all together. In the meantime, the position calls for further research into solutions to reduce numbers of additional male offspring and for humane methods of killing surplus animals on-farm.
The dairy and egg industries have been advised to adopt a ‘3Rs’ (reduce, replace, refine) approach to the rearing and slaughter of animals which are surplus to the requirements of the specific industries. Reduction recommendations include selecting for sex (a technology used quite frequently within the dairy farming community) and increasing the length of time that an animal can produce milk through selective breeding.
In the absence of these options, the position recommends raising male offspring for meat, with the caveat that calves and billy goat kids should be raised within UK high welfare schemes only.
In the absence of any reduce or replacement options, veterinary experts advise that killing should be undertaken in the most humane way and that all the animal’s welfare needs must be addressed prior to slaughter.
In line with BVA’s sustainable animal agriculture position, this policy recommends that when animals are killed, every effort should be made to make sure that the carcass is used. For example, the carcasses of male chicks killed by controlled atmospheric stunning can be used in animal feed, such as for reptiles and birds of prey.
BVA Junior Vice President, James Russell (pictured right) said: "Unwanted male production animals in the dairy and meat industries are an ethical challenge on a number of levels. Firstly, for the producer who may have animals with little or no commercial value. Secondly, for the consumer who may find the notion of these unused animals a difficulty. Our new joint position is based around the principle of ‘a life worth living’ and looks at ways that the veterinary profession can work with the farming community to reduce the numbers of animals that this affects and ensure that high welfare is always front and centre.
"If slaughter of affected animals is undertaken humanely, it is not a welfare harm per se, but greater measures should be taken to make sure that these decisions are made with minimal carcass wastage and an eye to the economic, emotional and environmental impact at a farm level.
"With greater public understanding of ethical and animal welfare issues faced by the industry, the promotion of farm assurance schemes and further research into alternative breeding options such as selective sex technology, we hope to reduce these numbers and improve the welfare of the animals involved."
BCVA President, Professor David Barrett said: "The number of unwanted male dairy calves has fallen substantially in recent years, due in part to more efficient milk production meaning we now need fewer dairy cows to produce the same volume of milk, as well as the use of breeding technologies that mean we can select for female calves. Nevertheless, surplus males are still produced. Provided these calves’ welfare is protected they should become part of the meat production supply chain either as high-quality UK farm assured veal or beef."
"As we strive for improved sustainability and increase efficient use of resource in food production, we need to use every product from dairying, including calves that can be reared for meat. Our entire industry needs to work together to create a robust supply chains for high quality, farm assured British dairy beef and veal and we need to help consumers understand they should embrace these products. They are very different from intensively reared veal of the type produced in systems previously banned in the UK."
The company says the battery-operated, dual-speed clipper has been specifically designed for a close cut to improve hygiene and make treatments easier.
Hefin Rowlands from Heiniger said: “The Opal Xtend will help vets with accurate hair removal for everyday tasks such as TB testing.
"It has been developed to be quieter, which will reduce stress, and has an interchangeable battery system to enable uninterrupted operation during periods of extensive use.
“An LED battery indicator provides forewarning to operators and additional batteries can be swapped out quickly and easily.
"Each battery will last up to 4 hours and the second battery only takes just over an hour to recharge.”
Heiniger claims that at 415 grams, the clipper is one of the lightest cordless models available.
Hefin added: “It is particularly well suited to preparing animals for skin testing, wound treatments and scans including ultrasounds.”
Heiniger says the clipper is also a good fit for agricultural and equine users looking for a reliable and dependable machine that can stand up to demanding use.
https://www.heiniger.co.uk/product/opal-xtend/
The legislation will come into effect from May 2018, at which point businesses will have six months to comply. The penalty for failing to comply will be an enforcement notice to the business or prosecution.
In August 2017, the Secretary of State launched a consultation on the plans to deliver a manifesto commitment for CCTV to be required in every slaughterhouse in England in all areas where live animals are present, with unrestricted access to footage for Official Veterinarians.
A summary of responses published in November showed that of almost 4,000 respondents, more than 99% were supportive of the plans.
Environment Secretary Michael Gove said: "We have some of the highest animal welfare standards in the world and want to cement our status as a global leader by continuing to raise the bar.
"Introducing compulsory CCTV cameras in slaughterhouses is a further demonstration to consumers around the world that as we leave the EU, we continue to produce our food to the very highest standards.
"The previous reaction to the consultation highlighted the strength of feeling among the public that all animals should be treated with the utmost respect at all stages of life and be subject to the highest possible welfare standards."
The proposals will also give the Food Standards Agency’s (FSA) Official Veterinarians (OVs) unfettered access to the last 90 days of footage to help them monitor and enforce animal welfare standards.
BVA President John Fishwick said: "Mandatory CCTV in all areas of slaughterhouses will provide an essential tool in fostering a culture of compassion that could help safeguard animal welfare.
"We commend the Government’s commitment to provide Official Veterinarians with unrestricted access to the footage, which the veterinary profession has long been campaigning for.
"It is vets’ independence and unique qualifications that help ensure the UK will continue to have the highest standards of animal health, welfare and food safety post-Brexit."
Photo: Lititz, Pennsylvania. Hoisting a slaughtered steer in Benjamin Lutz's slaughterhouse, 1942. Wikipedia.
The responsible use of antibiotics termed critically important is an important strand in the UK policy to fight antibiotic resistance development.
However, NOAH says there is much confusion about which antibiotics should be considered within this group, with different organisations referring to different classes.
Donal Murphy, Head of Technical and Regulatory Affairs at NOAH said: "NOAH believes the classification and use of antibiotics in veterinary medicine should be driven and guided by the regulators, who are independent and make science based decisions and recommendations.
"Of course, all classes of antibiotics, whether critically important or not, should be used responsibly and guided by the principle outlined by the Responsible Use of Medicines in Agriculture Alliance (RUMA) who state they should be used 'as little as possible but as much as necessary'. The use of these important products in this manner can ensure that the availability and efficacy of antibiotics can be maintained to ensure animal health and welfare in the future."
You can download the briefing document here.
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
ECM of France, a specialist in veterinary ultrasound solutions, has launched VIRTUAL SCAN - an ultrasound scanner for pig farmers and veterinarians. ECM says the scanner offers an alternative to screenless A-Mode Doppler devices, cheaper ultrasound devices, which are often poor quality.
VIRTUAL SCAN weighs 450 grams. It is equipped with an internal five-hour battery and a 5MHz sector probe. ECM says the instrument is extremely easy to handle - all the user needs to do is switch it on and the hand-held instrument is instantly ready to perform an ultrasound on sows.
VIRTUAL SCAN is a compact device (11cm x 18.5cm x 4.5cm) and does not require an external cable. According to the company, it can be used in any livestock facility, even inside narrow, hard-to-reach stalls. The screen is positioned in such a way that the image is always visible.
Using ECM's scanner, pregnancy tests can be performed as early as 21 days after insemination, so it is possible to re-inseminate any unfertilised sow without wasting a costly additional cycle. The image is easy to interpret. After use, the VIRTUAL SCAN ultrasound instrument is easy to clean with a damp cloth or water.
ECM, which is headquartered in Angoulême (in south-western France), develops and manufactures specialist veterinary-science devices. The company also provides training in ultrasound techniques, the correct way to move the probe and how to interpret the ultrasound image.
For more information, please contact:
Simon QuarmbyHOLMEFIELD Farm ServiceAgriculture HouseMurton LaneMurtonYorkT019 5UF
tel : (44) 1904 481.490fax : (44) 1904 481.211email : simon@hfsvets.com
Or visit: http://www.agroscan.com/ and http://www.ecmscan.com/
Merial Animal Health has launched Locatim, an oral antibody supplement to aid calf scour management.
Manufactured from the colostrum of high health status cows that are hyper-immunised against E.coli, rotavirus and coronavirus, Locatim contains a guaranteed concentration of specific antibodies to enterotoxic E.coli F5 (K99).
Merial says that when given alongside the dam’s colostrum, Locatim provides enhanced protection against infection, reducing calf mortality due to neonatal diarrhoea caused by E.coli F5 (K99), and helping to protect calf health during the critical rearing period.
According to the company, a single 60ml oral dose provides direct transfer of these specific antibodies, giving local protection within the digestive tract and systemic protection following absorption through the intestinal mucosa.
For optimal absorption Locatim should be administered during the first four hours of life, but it can be given up to 12 hours after birth.
Locatim can be administered to every calf born during an outbreak of scour; at times of peak calving, when environmental challenge is high; or it can be used to enhance protection in individual calves identified as being at high risk of disease due to factors such as dystocia, weakness or the poor quality of the dam’s colostrum.
For information on purchasing stock contact your local Merial Animal Health territory manager.
The British Veterinary Association has welcomed the tightening up of sales of veterinary medicines on the internet but has expressed disappointment that the advertising of antimicrobials to farmers will continue.
The Veterinary Medicines Directorate has today published its response to the public consultation on the Veterinary Medicines Regulations, which are updated every year.
The new Regulations, which come into force in April 2011, introduce new controls on internet pharmacies meaning that only approved websites will be legally allowed to dispense and supply veterinary medicines. The controls will come into force in April 2012 and the BVA supports the use of a logo on approved websites to help consumers buy medicines from reputable sources.
The BVA has previously expressed concern that pet owners could inadvertently buy counterfeit veterinary medicines online and urges veterinary clients to seek advice from their vet and only buy from UK-based companies.
Harvey Locke, President of the BVA, said: "Without proper regulation online pharmacies could be sourcing drugs from overseas and selling counterfeit medicines that look genuine to unsuspecting pet owners. These medicines are placebos at best and dangerous at worst.
"We therefore welcome the VMD's decision to clampdown on irresponsible online retailers and provide a clear logo for approved websites that will give pet owners confidence.
"We have also asked the VMD to put a stop to the increasing problem of prescription fraud and we hope the tighter regulation announced today will be a step towards achieving that aim.
"However, we would urge all pet owners to continue talking to their vet about sourcing medicines from the internet to make sure the right drugs are bought and administered correctly."
In light of increasing concerns about the growth of antimicrobial resistance the VMD's consultation canvassed views on restricting the advertising of antimicrobials to farmers. The BVA says it supported a ban on advertising as a sensible approach to the responsible use of antimicrobials, and is disappointed that the VMD has decided not to go ahead with it. Mr Locke said: "New antimicrobials are heavily advertised by pharmaceutical companies to vets and farmers so it is vital that the message of responsible use is not lost.
"Antimicrobial resistance is a serious issue for both animal and human health and we are disappointed that the VMD is not restricting the advertising of these products to farmers. The pharmaceutical companies must now undertake to advertise responsibly.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets and farmers should work together to ensure antimicrobials are used prudently and responsibly."
CEVA Animal Health's live enzootic abortion vaccine, CEVAC® Chlamydophila, has been renamed CEVAC® Chlamydia and repackaged in a larger bottle size.
According to the company, infectious abortion, particularly enzootic abortion (Chlamydiosis) can wipe out up to 50% of lambs but strategic use of CEVAC Chlamydia, a live enzootic abortion vaccine, can help keep the flock safe. It can prevent abortion and also control excretion and the threat of infection. For added convenience CEVAC Chlamydia can be used on the same day as the toxoplasmosis vaccine. This can save administration time and money.
For extra efficiency with big flocks CEVAC Chlamydia is now available in a larger, 50 dose bottle in addition to the original 20 dose bottle. It is administered using a special multi-dose injector gun.
CEVA says that a strategic vaccination every four years will help flocks remain chlamydiosis-free. Routine preventative measures are also advised prior to mating and when new sheep are introduced to the flock, to ensure abortion and infection rates always remain as low as possible. All animals should be vaccinated in the first year, with replacements being vaccinated from six months of age, at least four weeks prior to tupping.
For further product information contact your local CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG or visit the website at www.ceva.uk.com
Novartis Animal Health has launched Zolvix, billed as the first truly novel anthelmintic class for livestock to be launched in more than 25 years, together with a new drenching system designed to make drenching faster, easier and more accurate.
Zolvix contains a new active ingredient, monepantel, which kills all key sheep gastro-intestinal nematodes (roundworms), including those resistant to the existing treatments.
According to the company, the development of this new drench follows the persistent challenge from worms that have developed resistance to the three other classes of drench - white (benzimidazole or 1-BZ), yellow (levamisole or 2-LV) and clear (macrocyclic lactone or 3-ML) and combinations of these. Zolvix has a unique mode of action and so forms a fourth generation of anthelmintic, which will be known as the 4- AD, or orange drench class
Novartis Animal Health has prioritised the UK and Ireland as key launch countries for Zolvix to provide their sheep farmers with an answer to the pressing challenge of increasing anthelmintic resistance.
Lesley Stubbings, an Independent sheep consultant and Sustainable Control of Parasites in Sheep (SCOPS) panel member, said: "Resistance has become an ever increasing threat since the last new anthelmintic group was introduced to the UK market more than 25 years ago. Zolvix offers farmers a valuable opportunity to maintain good worm control and prolong the effective life of the existing products. Following the SCOPS guidelines to carefully integrate Zolvix into worm control strategies, before the other groups fail, will allow our sheep industry to reap the full benefits of this new novel group."
A study carried out by Novartis in conjunction with the Hopkirk Research Institute showed that Zolvix treated sheep gained 33.5%, or 2.8 kg deadweight, more than sheep treated with a drench to which they were resistant.
Novartis Animal Health Brand Manager Simon Harris said: "Parasite resistance is a growing problem that decreases the productivity of sheep of all ages. Many veterinarians and farmers are concerned about this, with an increasing number of farmers reporting resistance to the three groups of wormers that have been available up to now, so the introduction of Zolvix is very timely."
At the same time, the company has also launched an award-winning new drenching system designed to offer 'a superior drenching experience for both animal and operator'. The new Optiline Drencher and Optivix backpack system were developed in collaboration with drenching specialists Simcro Tech Ltd.
The Optiline Drencher has already won several design and engineering awards, including a bronze award in the 2009 NZ BEST design awards, a coveted International Forum (IF) 2010 product design award from Germany and the prestigious Bayer Innovators Award for design and engineering.
It was also a finalist in the New Zealand Agritech Innovation Awards reached the finals in three categories of the 2009 New Zealand Trade and Enterprise International Business Awards.
The Optiline drencher is coupled with a durable, light Optivix backpack that has been specially tailored to provide left or right-handed operators with the same wide range of adjustment. It also has two drench cradles - at chest and hip level - to ensure maximum comfort.
Mr Harris said: "This drencher is best appreciated during use. Contact your local Novartis Animal health representative to arrange a trial."